Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC

Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC is a phase 2, interventional study registered as NCT07110103 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 20 participants, started 2025-10-31 and due to reach its primary completion in 2027-03-31. Interventions recorded: golidocitinib with PD-1 inhibitors. Conditions listed: SCLC; SCLC, Extensive Stage. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Histologically or cytologically confirmed ES-SCLC (stage IV \[any T stage, any N stage, M1 a/b/c stage\] according to the 8th edition of the AJCC TNM staging system for lung cancer, or T3-4 stage disease caused by multiple lung nodules and the disease is too diffuse, or the tumor/nodule volume is to". Sites: China. No results are recorded here; the registry entry is the source.